0,1,2,3,4,5,6,7
Table 6.1.7: Major phase III randomised trials of moderate hypofractionation for primary treatment,,,,,,,
"Study/
Author",n,"Risk, ISUP 
grade, or 
NCCN",ADT,RT Regimen,"BED, Gy Median","FU, mo",Outcome
"Lee, et al. 
2016 [660]","550 
542",low risk,None,"70 Gy/28 fx 
73.8 Gy/41 fx","80 
69.6",70,"5 yr. DFS 86.3% 
(n.s.) 
5 yr. DFS 85.3%"
"Dearnaley, 
et al. CHHiP 
2016 [661]","1,077/19 fx 
1,074/20 fx 
1,065/37 fx","15% low 
73% 
intermediate 
12% high","3-6 mo. 
before 
and 
during 
EBRT","57 Gy/19 fx 
60 Gy/20 fx 
74 Gy/37 fx","73.3 
77.1 
74",62,"5 yr. BCDF 
85.9% (19 fx) 
90.6% (20 fx) 
88.3% (37 fx)"
"De Vries, 
et al., 2020 
[667]","403 
392","30% ISUP 
grade 1 
45% ISUP 
grade 2-3, 
25% ISUP 
grade 4-5",None,"64.6 Gy/19 fx 
78 Gy/39 fx","90.4 
78",89,"8-yr. OS 80.8% 
vs. 77.6%
(p = 0.17)
8 yr. TF 24.4% 
vs. 26.3%"
"Catton, et al. 
2017 [663]",608,"intermediate 
risk 
53% T1c 
46% T2a-c",None,60 Gy/20 fx,77.1,72,"5 yr. BCDF both 
arms 85% 
HR: 0.96 (n.s)"
,598,"9% ISUP 
grade 1 
63% ISUP 
grade 2 
28% ISUP 
grade 3",,78 Gy/39 fx,78,,
